Trial reportJPEN. Journal of parenteral and enteral nutrition2026
Developmental outcomes after soybean oil vs mixed-oil intravenous lipid emulsions in neonates: A secondary analysis of a clinical trial.
Trial report in JPEN. Journal of parenteral and enteral nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Developmental outcomes after soybean oil vs mixed-oil intravenous lipid emulsions in neonates: A secondary analysis of a clinical trial.JPEN. Journal of parenteral and enteral nutrition · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundFatty acids make up a significant portion of brain mass. The choice of lipid injectable emulsion alters a patient's fatty acid profile. In neonates with intestinal failure dependent on parenteral nutrition, this is particularly concerning given their rapid brain development.
methodsWe randomly assigned 24 infants to receive soy oil lipid emulsion at 1 g/kg/day or mixed-oil lipid emulsion containing soy, medium-chain triglyceride, olive, and fish oils at 3 g/kg/day. We have previously reported data on intestinal failure-associated liver disease incidence with a 39-day median follow-up. We now report 3-year follow-up, nonprespecified neurodevelopmental screening outcomes using the Ages & Stages Questionnaires-3, a test composed of five domains.
resultsFor this follow-up analysis, 20 patients were included, 10 in each group. There was no difference in patient parameters between the groups at birth or screening. The mean ± SD peak direct bilirubin was not different between the two groups (soy 1.8 ± 1.4 mg/dl and mixed 1.2 ± 0.8 mg/dl; P = 0.265). There was also no difference when comparing the mean scores or rate of developmental delay for all five Ages & Stages Questionnaire-3 domains between treatment groups. There was no correlation between peak direct bilirubin, gestational age, or days of lipid and domain scores.
conclusionIn this follow-up study of children who had previously received soy oil lipid reduction or a mixed lipid, there was no difference in development at 3 years. Given that this is a secondary outcome from a pilot trial, additional studies powered for developmental differences are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.